Chemical inhibitors of 1700011I03Rik can target various signaling pathways and enzymatic activities that are likely to be involved in the regulation of this protein's function. Wortmannin and LY294002, both known as phosphoinositide 3-kinases (PI3K) inhibitors, can reduce the activity of 1700011I03Rik by altering phosphoinositide signaling, a key pathway for numerous cellular processes including cell growth and survival. Inhibition of PI3K can disrupt the downstream signaling that may be critical for the proper functioning of 1700011I03Rik. Similarly, rapamycin, an mTOR inhibitor, can decrease the activity of proteins in the mTOR pathway, which includes 1700011I03Rik. The mTOR pathway is integral to cell growth and metabolism, and its inhibition can lead to reduced activity of associated proteins.
Further, Dasatinib and PP2, as inhibitors of Src family kinases, can decrease phosphorylation and consequently the activity of 1700011I03Rik if it is a substrate of Src-mediated phosphorylation. U0126 and PD98059 are inhibitors of MEK1/2, and their role in inhibiting the MEK/ERK pathway can lead to reduced activity of 1700011I03Rik by limiting signals for cell proliferation and differentiation that are typically mediated through this pathway. SP600125 and SB203580, which inhibit JNK and p38 MAPK respectively, can reduce the activity of proteins regulated by these stress-activated signaling pathways, potentially including 1700011I03Rik. Y-27632, a ROCK inhibitor, can disrupt Rho/ROCK pathway signaling, thereby potentially reducing the activity of 1700011I03Rik if it is regulated by this pathway. PD173074, an FGFR inhibitor, can decrease the activity of 1700011I03Rik by inhibiting FGFR signaling, which is crucial for processes such as cell growth and angiogenesis. Lastly, SL327, another MEK1/2 inhibitor, can decrease signaling through the ERK pathway, which in turn can reduce the activity of 1700011I03Rik as part of this pathway's regulatory network. Each of these chemicals, by targeting specific enzymes and pathways, can play a role in inhibiting the function of 1700011I03Rik by disrupting the protein's regulatory signaling mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits phosphoinositide 3-kinases (PI3K), which may be crucial for the downstream signaling affecting 1700011I03Rik activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially reducing activity of 1700011I03Rik through altered phosphoinositide signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which could lead to decreased activity of proteins in the mTOR pathway including 1700011I03Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits Src family kinases, possibly reducing phosphorylation and activity of 1700011I03Rik if linked to Src-mediated pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Inhibits Src family kinases, potentially reducing phosphorylation of 1700011I03Rik if it is a Src kinase substrate. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2, possibly leading to reduced ERK pathway signaling and subsequent activity of 1700011I03Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which may lead to decrease in ERK pathway signaling and therefore 1700011I03Rik activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
Inhibits JNK, potentially reducing activity of proteins regulated by JNK signaling including 1700011I03Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, which could lead to decreased activity of 1700011I03Rik if it is part of the p38 MAPK pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits ROCK, potentially reducing activity of 1700011I03Rik if it is regulated by Rho/ROCK pathway. |